68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results

[1]  M. B. Karakullukcu,et al.  c-MET Receptor–Targeted Fluorescence on the Road to Image-Guided Surgery in Penile Squamous Cell Carcinoma Patients , 2021, The Journal of Nuclear Medicine.

[2]  M. V. van Alphen,et al.  Translation of c-Met Targeted Image-Guided Surgery Solutions in Oral Cavity Cancer—Initial Proof of Concept Data , 2021, Cancers.

[3]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[4]  U. Capitanio,et al.  Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. , 2020, European urology.

[5]  A. D’Angelo,et al.  An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). , 2020, Critical reviews in oncology/hematology.

[6]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[7]  K. Togashi,et al.  Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  M. Roberts,et al.  A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC) , 2019, Molecular Imaging and Biology.

[9]  L. Shen,et al.  68Ga-DOTATATE Uptake in a Soft Tissue Metastasis From Clear Cell Renal Cell Cancer. , 2018, Clinical nuclear medicine.

[10]  J. H. Kim,et al.  Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review , 2017, Oncotarget.

[11]  Bernd J. Krause,et al.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Charles Swanton,et al.  Renal cell carcinoma , 2017, Nature Reviews Disease Primers.

[13]  P. Schirmacher,et al.  MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker , 2016, Oncotarget.

[14]  T. Powles,et al.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[15]  Gerald Antoch,et al.  Evaluation of the Outcome of Lung Nodules Missed on 18F-FDG PET/MRI Compared with 18F-FDG PET/CT in Patients with Known Malignancies , 2016, The Journal of Nuclear Medicine.

[16]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[17]  Zsolt Szabo,et al.  Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT , 2015, Annals of Nuclear Medicine.

[18]  Siavash Yazdanfar,et al.  Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met , 2015, Nature Medicine.

[19]  R. Baum,et al.  Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. , 2014, Clinical Nuclear Medicine.

[20]  E. Demirci,et al.  68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  A. d’Amico,et al.  Effect of furosemide administration before F-18 fluorodeoxyglucose positron emission tomography/computed tomography on urine radioactivity and detection of uterine cervical cancer. , 2014, Nuclear medicine review. Central & Eastern Europe.

[22]  G. Gibney,et al.  c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. , 2013 .

[23]  U. Vaishampayan.  Cabozantinib as a Novel Therapy for Renal Cell Carcinoma , 2013, Current Oncology Reports.

[24]  M. Tsao,et al.  c-MET as a potential therapeutic target and biomarker in cancer , 2011, Therapeutic advances in medical oncology.

[25]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.

[26]  Yongchang Shi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[27]  K. Miller,et al.  Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma , 2011, BMC Cancer.

[28]  K. Rex,et al.  c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations* , 2008, Journal of Biological Chemistry.

[29]  Michael A S Jewett,et al.  Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. , 2007, The Journal of urology.

[30]  H. Kanetake,et al.  Presence of Phosphorylated Hepatocyte Growth Factor Receptor/c-Met Is Associated with Tumor Progression and Survival in Patients with Conventional Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[31]  E. Fishman,et al.  Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector ct and three-dimensional CT. , 2001, Radiographics : a review publication of the Radiological Society of North America, Inc.